short share outstand
initi coverag outperform
despit ip competit overhang believ complement
franchis durabl remain under-valued initi outperform
rate fair valu estim share alexion experienc weak
intellectu properti ip issu unit state eu threat
competit product durabl complement franchis central
thesi belief alexion remain leader atyp hemolyt
urem syndrom ahu paroxysm nocturn hemoglobinuria pnh
ultomiri transition/market expertis former compani alreadi
plan convert view achiev
supplement continu launch potenti market expans gener
myesthenia gravi gmg neuromyel optica spectrum disord nmosd
launch begin unit state second half see
best-in-class data scenario analysi base case assum biosimilar entri
unit state eu assum clinic success
price discount gmg peak revenu billion nmosd
peak revenu billion fv pipelin bull case assum
alexion win inter parti review ipr maintain ip protect yield
fair valu fv pipelin bear case assum competi-
tion biosimilar price discount competit program yield
fair valu fv pipelin base analysi believ
continu investor focu busi develop strategi execut
sinc alexion spent billion front busi develop
billion potenti mileston payment recent announc cfo
transit expect focu intensifi acknowledg larger
deal unlik leftov scar syngeva transact string
pearl approach could view favor compani supplement
true growth driver clinic de-risk perspect larger
deal see valu pipelin drug asset allakoss monoclon
antibodi mab variou eosinophil mast-cell-rel diseas gossam
bio oral antagonist could realli bolster compani pipelin
compani foray new modal see passag aav gene therapi
compani target rare diseas gene therapi compani
target rare skin diseas value-cr platform play
risk invest primarili competit relat compani comple-
ment franchis alexion involv on-going ipr relat soliri patent
unit state well recent neg patent extens decis eu
global biopharmaceut compani focus discoveri develop
commerci therapi rare ultra-rar diseas
pleas refer import disclosur page analyst certi cation page
william blair liat seek busi compani cover research report
result investor awar rm may con ict interest could ect ob-
jectiv report report intend provid person invest advic opinion
recommend herein take account individu client circumst object need
intend recommend particular secur nancial instrument strategi particular
client recipi report must make independ decis regard secur
report consist execut summari compani thought valuat accom-
pani slide deck detail commerci product soliri ultomiri strensiq
kanuma clinic pipelin busi development/collabor access slide deck
separ model pleas contact william blair salesperson
exhibit show npv analysi free cash alexion conserv
estim termin growth rate discount rate yield fair valu per share
current market product individu indic market model complement franchis
see appendic i-iv assign probability-adjust fair valu per share compani
late-stag pipelin product outsid wilson diseas
warm autoimmun hemolyt anemia waiha total fair valu estim
npv free estim
pv fcff
exhibit show compar compani cohort center biotech strong fran-
chise drive outsiz portion total revenu eylea regeneron multipl sclerosi
etc base mean compani averag ev revenu multipl
time forward price-to-earnings multipl time multipl
non-gaap ep estim alexion use discount rate yield fair valu estim
line npv estim exhibit
dollar million except price
addit base-cas valuat also calcul potenti bull- bear-cas scenario
base potenti competit compani complement franchis recent
grant ipr challeng patent extens soliri pnh
acknowledg potenti overhang yearlong process also believ compani
current valuat assum penetr market biosimilar
impact histor initi phase clinic trial biosimilar abp
treatment pnh product still clinic regulatori risk certain countri
eu soliri patent protect cover composit matter europ
soliri orphan drug exclus ahu gmg respect exhibit
show patent expir soliri alexion grant patent extens pnh
eu evalu potenti appeal
note pnh convers rate ultomiri faster guidanc date
compani recent note convers rate germani roughli two-month faster pace
launch convers unit state exhibit show earli ultomiri launch
perform well compar orphan diseas launch even consid switch
environ still consid impress
select orphan drug launch quarter
use three lever analys market penetr rate indic particularli import
gmg nmosd biosimilar entry/pr unit state eu rest world
peak ultomiri convers rate exhibit show revenu trajectori complement
franchis scenario
exhibit show summari base- bull- bear-cas assumpt ahus/pnh conver-
sion ultomiri biosimilar price gmg nmosd peak revenu
discount soliri price
convers rate pnh
convers rate ahu
sales/year pnh
sales/year ahu
sales/year gmg
penetr gmg
sales/year nmosd
penetr nmosd
sale million
commercial-stag global biopharmaceut compani focus
develop treatment rare diseas four areashematolog nephrolog neurolog
metabol neonat fc receptor fcrn initi compani focus develop com-
plement inhibitor two approv complement inhibitor soliri ultomiri
market addit alexion two approv enzym replac therapi ert kanuma
strensiq treatment life-threaten metabol disord apart approv
product compani develop program includ approv product ad-
dition indic new pipelin addit product candid
soliri approv complement inhibitor major revenu contributor roughli
second quarter compani human mab block termin complement
activ inhibit particular complement compon immun system therefor treat
associ chronic disord therapeut area hematolog nephrolog
neurolog initi soliri approv treatment pnh ahu
respect receiv fda approv treatment anti-acetylcholin receptor
achr antibody-posit gmg compani note expect gmg would provid
largest patient volum soliri among approv indic base preval
diseas recent fda approv soliri treatment antibodi
posit nmosd anticip launch begin second half compani
alreadi nmosd eu also receiv prioriti review japan
alexion complement inhibitor ultomiri also human mab comple-
ment inhibitor provid inhibit eight week mechan action similar soliri
ultomiri approv treatment pnh bla accept fda treatment
ahu pdufa date octob expect lead approv addi-
tion compani initi phase trial ultomiri gmg plan initi phase trial
nmosd end year regard transit soliri ultomiri juli
compani alreadi convert patient ultomiri pnh plan convert
ultomiri receiv approv indic compani would look
move patient soliri ultomiri addit approv indic apart
complement inhibitor alexion two approv ert strensiq kanuma treatment
hypophosphatasia lysosom acid lipas lal-d respect strensiq
target ert approv therapi patient restor underli
genet defect metabol process therefor prevent revers complic
kanuma recombin form human lal enzym approv ert lal-d
alexion pipelin target diseas four therapeut area hematolog nephrolog neurolog
metabol fcrn exhibit total compani develop program metabol
diseas lead product candid oral copper bind
agent address underli caus wilson diseas uniqu mechan action
access bind copper serum promot remov liver compani
phase trial wilson diseas fcrn portfolio lead candid
human mab inhibit interact neonat fcrn igg
igg immun complex potenti improv treatment mani rare igg-medi diseas
mab evalu waiha gmg compani plan initi pivot
trial indic earli alexion treat refractori gmg patient popul
unit state soliri seek approv ultomiri refractori
moder patient popul howev compani plan includ rest
gmg popul unit state
hematolog compani two product candid ultomiri treatment
al amyloidosi hsct-tma respect chimer mab kappa
lambda light chain indic alexion plan initi phase ii/iii trial
half neurolog mention ultomiri pivot trial gmg
nmosd indic compani also plan start ultomiriss phase i/ii trial
treatment amyotroph later sclerosi al primari progress multipl sclerosi ppm
overal compani expect expand address patient popul
patient current market product patient pipelin
italic plan initi
alexion plan initi phase studi ultomiri nmosd also plan report
dose-optim phase ib/iia data treatment waiha compani also plan
start sever late-stag clinic program show compani near-term
catalyst exhibit
timelin event
approv subq dose
ultomiri pnh
data phase trial
wilson
complet phase
studi
treatment
approv gmg iv
approv
approv ultomiri
nmosd iv
potenti file
approv
gmg waiha
ultomiri ahu pdufa
date octob
approv ultomiri
ahu
initi phase trial
ultomiri gmg
initi phase trial
ultomiri nmosd
initi phase human
proof-of-concept studi
ultomiri al
eu approv ultomiri
pnh
clinic studi ultomiri
ppm
data phase i/ii trial
gmg
target pnh
patient ultomiri
initi phase hsct-
initi phase ii/iii trial
al
initi pivot trial
gmg
data phase studi
sad/mad
complet phase
studi apelli
treatment pnh
initi first human studi
discuss select competit program investor focus relat
alexion complement franchis complet pictur complement landscap see
accompani powerpoint slide deck
apelli develop inhibitor treatment paroxysm nocturn hemoglobinuria
evalu monotherapi mg soliris-nav pnh patient phase ii
paddock studi abl reduc ldh level normal similar ultomiri
addit improv mean hemoglobin level g/dl demonstr impact
intravascular extravascular hemolysi improv reticulocyt bilirubin level apl-
also evalu pharoah trial enrol six patient treat
day continu treatment two year four patient still on-going two discontinu
show potenti improv soliri outcom add-on therapi four four patient
treat abl transit monotherapi evalu random
open-label phase pegasu trial treatment pnh administ
mg roughli patient twice weekli four month subsequ put open-
label follow-up primari outcom chang hemoglobin level
baselin data anticip program fourth quarter
develop soliri biosimilar date compani share clinic
data publicli complet phase studi enrol healthi subject compani
on-going phase trial random double-blind studi pnh patient receiv
either week follow soliri week soliri week follow
week primari endpoint studi hemolysi measur ldh
parallel crossov comparison month month respect
argenex develop efgartimod antibodi fragment thought degrad
disease-caus autoimmun antibodi treatment sever autoimmun diseas relat
igg gmg immun thrombyctopenia itp phase ii trial treat patient four
iv dose mg/kg placebo three-week period follow
eight-week observ period result phase ii trial publish neurolog
howard et al neurolog show treatment provid sustain improv
differ clinic scale mg-adl qmc mgc reduct respect scale reach
maximum point reduct qmg scale point mg-adl scale point
mgc scale point respect placebo valu point
point point point lastli anti-achr autoantibodi level decreas earli
day infus maxim reduct reach patient
except one reduct maintain day level gradual increas
approach baselin level eight week last dose evalu
random double-blind phase adapt trial treatment gmg expect enrol
patient primari endpoint percentag mg-adl respond achr-antibodi
seroposit popul studi estim primari complet date june
estim studi complet date novemb also evalu long-term
single-arm open-label phase studi expect complet june
ra develop zilucoplan synthet macrocycl peptid bind
inhibit cleavag treatment gener myasthenia gravi immune-medi
necrot myopathi decemb compani present top-lin result phase
ii studi zilucoplan treatment gmg forty-four patient present broad gmg
restrict refractori enrol trial treat placebo mg/kg zilucoplan
mg/kg zilucoplan week subsequ long-term extens arm end
period mg/kg reduc quantit myasthenia gravi qmg
myasthenia gravi activ daili live mg-adl score respect compar
placebo reduc score respect mg/kg
dose also reduc qmg mg-adl score compar placebo
respect data well pool analysi cohort achiev primari
endpoint chang qmg score week secondari endpoint chang mg-adl
score week addit patient achiev minim symptom express
mg/kg dose week treatment compar patient mg soliri
week patient treat mg/kg dose requir rescu ivig plex
patient treat mg/kg dose patient treat placebo
base convers regulatori agenc ra plan initi singl pivot
random double-blind placebo-control phase studi second half
suggest compani present top-lin result half
roch develop satralizumab inhibitor treatment nmosd satralizumab
studi two phase trial monotherapi sakurastar combin sakuraski
sakurastar patient administ satralizumab mg placebo subcutan
week follow treatment everi four week primari endpoint studi
time relaps determin independ review committe result
pivot phase sakurastar studi show satralizumab monotherapi reduc risk
relaps compar placebo addit satralizumab reduc
rate relaps compar placebo subgroup patient
seroposit antibodi indic sever diseas cours overal
treat patient relaps free week treat patient relaps free
week compar placebo respect seroposit
group treat patient relaps free week treat patient
relaps free week compar patient given placebo respect
sakuraski patient administ satralizumab mg placebo subcutan
combin baselin therapi azathioprin mycophenol mofetil and/or corticosteroid
week subsequ everi four week primari endpoint studi time
relaps determin independ review committe result sakuraski
studi examin satralizumab combin baselin therapi show reduct
relaps risk across seroposit seroneg popul compar
placebo proport patient seriou advers event similar activ
placebo arm common advers event satralizumab group urinari tract
infect upper-respiratori infect nasopharyng headach
develop medimmun inebilizumab monoclon antibodi
treatment nmosd n-momentum studi enrol patient receiv either
two introductori dose inebilizumab mg placebo day day pivot n-
momentum studi show inebilizumab reduc risk relaps compar placebo
seroposit patient week treatment addit
igg seroposit patient treat inebilizumab relaps free compar given
placebo across entir patient popul includ seroneg patient inebilizumab
reduc risk relaps compar placebo studi met second-
ari endpoint well includ reduct worsen baselin expand disabl
statu scale edss score inebilizumab vs placebo reduct
nmosd-rel hospit inebilizumab vs placebo
reduct frequenc cumul total activ mri lesion inebilizumab vs
placebo although statist differ secondari endpoint
visual acuiti inebilizumab favor safeti compar placebo viela bla
inebilizumab august addit fda grant compound orphan drug designa-
tion breakthrough therapi design ema grant orphan drug design
potenti competit product entri complement franchis
increas focu alexion busi develop strategi bolster compani revenu growth
long term ad recent cfo transit paul clanci aradhana
sarin compani current chief strategi busi use free cash estim
limit debt-to-ebitda ratio time cash hand estim
compani roughli billion cash spend deal list two categori asset
believ would valu gener addit smaller compani could inter-
estimate see accompani present pipelin drug asset gene therapi platform
soliri ultomiri alexion shown abil capit drug sever
differ applic believ two compani
asset autoimmun space could intrigu alexion potenti add pipelin
acquisit licens agreement gossam oral antagonist prosta-
glandin receptor develop treatment moder sever eosinophil
asthma chronic rhinosinus nasal polyp chronic spontan urticaria allakoss
monoclon antibodi develop treat eosinophil mast-cell-
relat diseas recent compani report posit result phase ii trial patient
eosinophil gastriti eosinophil gastroenter eosinophil esophag
rare diseas leader alexion could bring establish gene therapi platform
increas expertis modal see clinic success rare ultra-
rare diseas indic passag privat compani focus aav gene therapi treat
rare monogen disord current helm stephen squinto co-found alexion
compani plan initi clinic trial gangliosidosi frontotempor dementia
half krabb diseas second half focus gene
therapi rare skin diseas use star-d platform technolog com-
pani shown proof-of-concept clinic data phase i/ii studi dystroph epidermolysi
bullosa deb lead candid guid pivot trial initi fourth
quarter alreadi receiv rmat prime design view would expand
alexion technolog platform remain focus rare diseas
complement franchis may risk ip perspect biosimilar entri like
lower price potenti particularli territori outsid unit state
alexion revenu highli depend sale soliri unit
state patent soliriss composit matter expir certain countri
europ composit matter expir soliri orphan drug exclus gmg
unit state ahu gmg late respect europ
howev entri biosimilar nonexclus indic could take away market share
compani particularli pnh unit state eu ahu unit state
histor biosimilar bare made dent biolog market howev govern
focu reduc healthcar spend payer unwilling reimburs higher-pr drug could
chang trend could affect alexion revenu
competit risk exist alexion soliri ultomiri program
transit patient ultomiri find patient diseas add potenti
market exclus soliri set expir unit state eu
compani need shift patient soliri ultomiri treatment pnh maintain
market share entri less expens biosimilar would make transit also
soliri recent approv treatment nmosd rare diseas compani need
penetr smaller market maintain top-lin growth alexion addit pipelin
candid also target rare diseas patient necessari commerci success
product recov cost develop alexion need price therapi higher obtain-
ing reimburs govern insur higher-pr product critic product
success also countri price subject government control must approv
market drug add risk
soliri ultomiri approv treatment pnh howev futur compani
may compet new novel drug pharmaceut current develop treatment
pnh addit biosimilar pnh alexion may compet amynda pharmaceut
vartiss tesidolumab nomacopan addit akari develop
nomacopan treatment ahu anoth indic target soliri alnylam pharmaceu-
tical also test cemdisiran treatment ahu alexion may face competit
zilucoplan treatment gmg compani may face competit
compani work mechan complement inhibitor
sutimlimab although drug indic alexion compani could start
develop drug indic alexion mechan action
dr hantson serv chief execut sinc march
juli led spin-off baxalta public compani baxter serv
presid baxter bioscienc spin-off serv presid chief execu-
tive baxalta join alexion dr hantson also serv member board
director baxalta may join baxter establish bioscienc divis led
develop robust pipelin new product launch new product
held variou leadership role novarti includ ceo pharma north america ceo
europ presid pharma canada join novarti work johnson
johnson year market r&d role dr hantson hold ph
motor rehabilit physic therapi master degre physic educ
tion high secondari educ univers louvain belgium
paul clanci serv chief alexion sinc juli respons includ
investor relat inform technolog secur activ also serv board
director incyt corpor join alexion clanci work
execut vice presid chief also member
execut committe prior work year variou
role relat strategi gener manag clanci hold columbia
univers sc babson colleg septemb compani announc
clanci would step cfo serv senior advisor
aradhana sarin chief strategi busi
dr sarin alexion sinc novemb year experi global
institut join alexion manag director healthcar corpor
invest bank citi global bank also work ub morgan
bank career train medic doctor india receiv train univers
delhi receiv stanford busi school also serv board
septemb compani announc dr sarin would becom cfo
third quarter result
brian goff serv chief commerci alexion sinc june lead global com-
mercial oper respons compani oper north
america emea japan latin america goff expertis commerci oper
across multipl therapeut area also experi manag variou function role
 medic affair manufactur qualiti mani biopharmaceut compani
join alexion serv chief oper member board director
neurov prior goff execut vice presid presid hematolog divis
baxalta previous serv global hemophilia franchis head baxter healthcar
initi stage career held sales-and-market posit novarti johnson
johnson pharmaceut divis goff hold wharton school univers
pennsylvania econom skidmor colleg
dr orloff serv head research develop alexion sinc june role in-
clude strengthen compani clinic pipelin research program improv produc-
tiviti overse regulatori medic affair support busi develop dr orloff
experi year biopharmaceut industri expertis across stage clinic
nonclin develop includ develop medicin rare diseas join
alexion work novelion head current member novelion board
director previous dr orloff global head chief baxalta
term advanc compani pipelin led regulatori approv uniqu product
two devic prior held execut posit baxter merck serono novarti
merck research laboratori move biopharmaceut industri
work yale school medicin seven year complet medic train
univers pittsburgh medic center yale school medicin dr orloff hold
univers vermont colleg medicin dartmouth colleg
john orloff execut vice presid head research develop
alexion report revenu billion second quarter complement franchis
contribut billion soliri million ultomiri million metabol franchis
contribut million strensiq million kanuma million revenu heavili skew
toward soliri may chang ultomiri obtain approv addit indic patient
shift soliri ultomiri complement franchis revenu model assum three
like scenario bull base bear base assumpt price penetr conver-
sion rate soliri ultomiri base bull bear case project total revenu
billion billion billion compound-annual-growth-rate
respect exhibit within complement franchis contribut billion billion
billion compound-annual-growth-rate respect
total revenu bull base bear case
exhibit follow page show estim complement franchis revenu
contribut indic everi scenario note gmg nmosd like take
major revenu contributor soliris/ultomiri long term
indication-wis sale percentag complementari franchis
indication-wis complementari sale base
indication-wis complementari sale bull
indication-wis complementari sale bear
histor manag guid revenu conserv also rais guidanc quarterli
releas throughout year instanc releas fourth quarter earn compani
guid total revenu within rang million increas
rang million third quarter earn releas howev
alexion report revenu million greater
initi last guidanc respect base prefer remain slightli
higher end guid rang estim revenu million
greater compani initi last provid guidanc
forecast non-gaap expens total revenu third quarter
fourth quarter total revenu thereaft similarli non-gaap
sg expens estim total revenu third quarter fourth
quarter total revenu beyond alexion non-gaap operat-
ing margin second quarter expect decreas
oper expens ramp like increas focu clinic trial
compani grow pipelin lastli estim compani gener non-gaap ep
dilut base bull bear case respect exhibit
base-cas incom statement shown exhibit
non-gaap ep bull base bear case
june alexion billion cash equival short-term market
secur compani receiv inventori payabl billion million
million respect end second quarter expect billion
million million respect end sinc new manag join
second quarter compani debt lower billion second quarter
billion second quarter project debt declin per
compani repay schedul period billion compani
engag new deal june alexion million share outstand exhibit
show balanc sheet project
alexion gener million cash oper second quarter expect
metric remain posit project horizon estim com-
pani gener free cash billion increas billion
assum capit expenditur million million
million show cash project exhibit
impair acquir in-process
amort purchas intang
impair intang asset
chang fair valu conting
incom loss tax
unreal loss gain debt secur
unreal gain pension oblig
unreal gain loss hedg activ net ta
 total revenu
sg total revenu
 total revenu
sg total revenu
sourc compani report william blair estim
equival
prepaid expens current asset
properti equip net
right use oper asset
account payabl accru expens
current portion long-term debt
current portion conting consider
addit paid capit
accumul comprehens incom loss
total liabil prefer stockhold equiti
sourc compani report william blair estim
oper
adjust reconcil net loss net cash provid use oper activ
depreci amort expens
impair asset
chang fair valu conting consider
unreal loss gain forward contract
unreal gain equiti invest
non-cash expens acquir ipr
payment conting consider
premium amort available-for-sal secur
chang oper asset liabil
prepaid expens right use oper asset asset
account payabl accru expens leas liabil liabil
net cash provid use op activ
invest
purchas available-for-sal debt secur
proce matur sale available-for-sal debt secur
purchas mutual fund relat nonqualifi defer compens plan
proce sale mutual fund relat nonqualifi defer compens plan
purchas properti plant equip
purchas strateg invest
purchas intang asset
net cash use invest activ
financ
proce revolv credit facil
payment term loan net
payment revolv credit facil
repurchas common stock
net proce issuanc common stock share-bas compens arrangem
payment conting consider
repay development-rel grant
net cash provid financ activ
effect exchang rate chang cash cash equival restrict cash
net chang cash cash equival restrict cash
cash equival restrict cash begin period
cash equival restrict cash end period
sourc compani report william blair estim
patient pnh treat complement
treatment per vial
dollar thousand
 complement pnh market
 complement sale pnh
convers ultomiri
 soliri sale pnh
european complement pnh market
european complement sale pnh
convers ultomiri
european soliri sale pnh
asia-pacif complement pnh market
asia-pacif complement sale pnh
convers ultomiri
asia-pacif soliri sale pnh
intern complement sale pnh
convers ultomiri
intern soliri sale pnh
total complement sale pnh
total soliri sale pnh
patient pnh treat complement
treatment per vial
patient pnh treat complement
treatment per vial
dollar thousand
total ahu patient elig therapi
patient complement ahu
treatment per vial
 complement sale ahu
convers ultomiri
 soliri sale ahu
total ahu patient elig therapi
european complement sale ahu
convers ultomiri
european soliri sale ahu
total ahu patient elig therapi
asia-pacif complement sale ahu
convers ultomiri
asia-pacif soliri sale ahu
intern complement sale ahu
convers ultomiri
intern soliri sale ahu
patient complement ahu
treatment per vial
patient complement ahu
treatment per vial
total complement sale ahu
total soliri sale ahu
dollar thousand
patient rgmg elig complement therapi
complement penetr
patient rgmg treat complement
treatment per vial
 complement sale refractori rgmg
convers ultomiri
 soliri sale refractori rgmg
patient rgmg elig complement therapi
complement penetr
patient rgmg treat complement
treatment per vial
european complement sale refractori gmg
convers ultomiri
european soliri sale refractori gmg
patient rgmg elig complement therapi
complement penetr
patient rgmg treat complement
treatment per vial
asia-pacif complement sale refractori gmg
convers ultomiri
asia-pacif soliri sale refractori gmg
convers ultomiri
total complement sale rgmg
total soliri sale rgmg
dollar thousand
total popul unit state
preval nmosd
incid nmosd
patient relaps nmosd
patient
patient
patient nmosd elig complement therapi
complement penetr
patient nmosd treat complement
treatment per vial
 complement sale nmosd
convers ultomiri
 soliri sale nmosd
total popul
preval nmosd
incid nmosd
patient relaps nmosd
patient
patient
complement sale nmosd
convers ultomiri
soliri sale nmosd
total popul asia-pacif
preval nmosd
incid nmosd
patient relaps nmosd
patient
patient
patient nmosd elig complement therapi
complement penetr
patient nmosd treat complement
treatment per vial
patient nmosd elig complement therapi
complement penetr
patient nmosd treat complement
treatment per vial
asia-pacif complement sale nmosd
convers ultomiri
asia-pacif soliri sale nmosd
convers ultomiri
total complement sale nmosd
total soliri sale nmosd
price common stock public compani mention report follow
despit ip competit overhang
tabl content
program develop
busi develop collabor
previous ceo baxalta year
experi biopharma
previous vice-president gener counsel alereinc
previous chief strategi busi offic
previous vice-president head novelion
previous neurov
john orloff vice presid head
previous chief human resourc offic
previous chief complianc offic hess
previous vice-president global commun
cultur baxalta
commun cultur sinc april
strong second-quart result increas ep guidanc
 total revenu
sg total revenu
focus indic develop posit compani
potenti launch year
hematolog nephrolog
approv ultomirisfor
pnh
patient ultomirisbi
initi phase hsct-
al
initi pivot trial
gmgand
data phase studi
sad/mad
complet phase
studi
apelli treatment
ultomiri ahu
pdufa date octob
initi phase trial
ultomiri gmg
initi phase trial
initi phase
studi ultomirisfor al
eu approv ultomiri
pnh
clinic studi ultomiri
ppm
data phase i/ii trial
gmgand
initi first human
studi
approv subqdos
ultomirisfor pnh
data phase trial
wilson
complet phase
studi
treatment
approv gmgwith iv
subqdos
approv
wilson diseas
approv ultomirisfor
nmosd iv subq
potenti file
approv
gmgand waiha
ultomiri launch show strength compar
commerci launch drug diseas
commerci launch drug diseas
complement pathway lead recruit
inflammatori agent cell death
complement system part immun
system complement antibodi
complement system activ
classic pathway lectin pathway
altern pathway activ
differ initi molecul converg
altern pathway continu
activ low level activ
limit presenc endogen
present
host cell foreign pathogen
immun complex
m/o mammalian
janewayet al immunobiolog immun system diseas
caus complement-medi hemolysi
progress ultra-rar blood disord
incid rate per million
estim preval
averag age onset year old
caus clonal expans
hematopoiet stem cell hsc
acquir somat mutat x-link
gene result lack complement
surfac protein link
loss complement regulatori surfac
protein result
prior soliri pnh patient
die within year diagnosi
sign symptom pnh
short breath
death
affect patient
caus death
soliri becam first fda-approv treatment pnh
long-act human mabthat bind complement inhibit
cleavag
sourc compani report duboi cohen british journal clinic pharmacolog
solirispati evid extravascular
partial respond reduct
transfus requir
without abrog blood
minor respond due
chang blood transfus
requir reduct
hemoglobin level
mark reduct ldh level
reduct
without
abrog blood
transfus independ
transfus independ
caus chronic complement activ
rare blood disord incid peopl per year unit state
estim preval unit state
caus genet mutat trigger event pregnanc infect cancer certain
medic caus uncontrol chronic activ complement system direct
cell line blood vessel kidney
character thrombot microangiopathi format blood clot small blood
prior soliri ahuspati die develop end-stag renal diseas
first ahusbout patient die renal damag requir dialysi within first
year diagnosi
sourc nation librari medicin compani report
soliri becam first fda-approv treatment ahu
proport patient achiev complet tma
respons week
proport patient
platelet count median chang baselin
patient low platelet count baselin characterist ahu
 mean platelet count sd
median time rang platelet count normal day
week mean improv platelet count baselin
patient receiv tpe/pi baselin none requir tpe/pi
end studi period
improv platelet count rapid sustain throughout
studi period
median time complet tma respons rang week
ci patient achiev hematolog
normal median time day rang day
neuromuscular diseas caus antibodi
block alter destroy acetylcholin
ach receptor neuromuscular junction
nmj prevent muscl contract
result skelet muscl weak
achreceptor autoantibodi activ
complement system insert
muscl membran destroy normal
motor endplat fold degrad
thymu gland anticholinesteras slow
breakdown achat nmj
immunosuppress plasmaresisto
incid rate roughli case per
 preval roughli
nation institut neurolog disord stroke
block ach
bind achr
soliri first approv complement inhibitor gmg
first fda-approv treatment patient
gmgin year
approv eu japan canada
long-term safeti profil consist
hospit rescu therapi
improv seen solirisin regain
maintain three year
event rate report
year prior
start
sourc compani report muppidiet al muscl nerv
chang baselin open-label extens studi mean mg-
event rate exacerb
event rate mg-relat
year prior
start
complement activ
autoimmun diseas caus
inflamm optic nerv spinal
cord result paralysi sight
larg mediat anti-aquaporin
antibodi activ complement
pathway result astrocyt death
oligodendrocyt loss subsequ neuron
character step-wis function declin
follow attack
occur per
fda-approv medic
mainten nmosd cellcept rituxan
imuran prescrib off-label
recruit activ
soliri recent approv unit state nmosd
patient phase prevent studi
relaps free week soliri
relaps free three year
approv fda june launch
registrationalfil eu japan
potenti approv
proport patient relapse-fre prevent studi
time studi period week
soliri patient growth acceler
approv new indic
growth gmg
best alexion launch
soliri gmg
potenti soliri
approv nmosd
expertis pnh
ultomiri gener inhibitor
potenti standard
approv fda decemb pnh
recent approv europ japan treatment pnh germani launch underway
patient safe switch soliristo ultomiri
human mabthat specif bind protein complement cascad inhibit
breakdown
develop use xencor santibodi half-lif prolong technolog xtend use
address intravascular breakthrough hemolysi seen solirisdu inadequ
decreas dose everi week everi eight week
aim convert patient ultomiriswithin two year launch
ultomiri provid immedi complet sustain
inhibit complement inhibitor patient
efficaci ultomirisi inferior soliri
compar soliri
ta decreas break-through hemolysi
ultomirisimmedi complet
remov free wherea solirispati
variabl low-level
treatment effect co-primari secondari efficaci endpoint
chang facit- fatigu
mean ci free concentr ultomiri ravulizumab
ultomiri similar safeti profil improv efficaci
treatment effect primari secondari efficaci endpoint
chang facit- fatigu
patient advers event
patient either treatment group
pain extrem
patient seriou advers event
patient advers event lead
withdraw studi drug
patient seriou advers
event lead withdraw studi drug
aim convert pnh patient soliri
ultomiri within year launch
aim convert patient ultomiri
convert juli
pnh patient prefer ultomirisov
safeti data support safe switch wash
period need
commerci live specif
pnh patient convert ultomiri
scenario gener ate market share
current market presenc dose regimen bode
ultomiri competit landscap
mode
mechan action
blockag activ
blockag activ
blockag activ
stage clinic
biosimilar soliri
biosimilar soliri
inhibit activ
peptid macrocycl subq alloster inhibit
inhibit hepat
express
pegyl peptid subq inhibit activ
inhibit activ
inhibit ap
inhibit ap
data share date program phase studi enrol
phase studi enrol patient
estim primari complet date septemb
estim studi complet date april
would like need discount penetr market
even frequent dose ultomiri
bear case solirisip expir launch three
phase ii studi reduc ldh level similar efficaci
phase ii studi dose increas patient
patient success withdrawn soliri
phase studi enrol patient
estim primari complet date decemb
estim studi complet date octob
upstream target greater infect risk peptid
ultomiri ahu pdufa date octob launch like
prioriti review fda
file regulatori review eu juli
file subqadministr week base phase studi
expect realiz discount annual solirismainten dose
compon primari endpoint
increas renal function
proport patient
often poor persist due frequent dose soliri
silent symptomolog cost
risk tma higher patient treatment
opportun improv complianc help reduc risk life-
threaten tma dose
expand ultomiri label gmg could captur greater
patient popul
expand treatment option patient
gmgwith ultomirisiv subq
initi phase trial
prior failur ist therapi requir
enrol mg-adl score
expect realiz discount annual
total gmg popul patient
refractori
gmg patient
potenti approv ultomiri nmosd
phase singl arm estim studi adult
result contemporan control
initi bridg
ultomirissc pend regulatori feedback
studi design bridg approach
expect realiz discount annual
leverag neurolog footprint prevent
result drive trial recruit optim
competit landscap ahu gmg nmosd spars
mode
mechan action
inhibit activ
inhibitiom hepat
express
antagonist
lp inhibit blockag
lp inhibit blockag
stage clinic
inhibit activ
complet phase ii trial top-lin data present decemb
significantli rapidli reduc qmg mg-adl score
initi phase trial data like
complet phase ii trial top-lin data publish
significantli reduc qmg mg-adl score briefli reduc
on-going phase trial expect complet
initi phase proof-of-concept trial ultomiri
amyotroph later sclerosi al
neurodegen diseas character
motor neuron degener lead
high mortal rate year diagnosi
estim address popul
japan
deposit motor end-plat
elev complement activ al serum
csf suggest role complement
cure al fda
radicava tiglutik
baselin
earli read futil
on-going phase trial pnh allow
approv ahu pend posit result
first patient dose
patient prefer iv subq
previous approv fda use
devic total infus time
visibl needl need reconstitut
year
hypophosphatasia character soft bone
caus inabl take miner
ultra-rar genet metabol disord due
mutat alkalin phosphatas
alpl gene character low
bone unabl take miner
calcium phosphoru result soft
without treatment infant
onset within first six month life
peopl
symptom
delay disproportion growth
gait abnorm
insuffici fractur
disabl impact abil
work
deform weight-bear limb
bone joint pain
sourc compani report nation organ diseas
muscl pain weak
diminish qualiti life includ
approv first approv
medicin treat perinatal/infantile-and
recombin glycoprotein contain
catalyt domain work replac
alkalin phosphatas allow phosphat
calcium bind improv bone health
surviv rate patient treat
strensiqat one year compar
expand effort educ appropri
competit product develop
first approv therapi treat underli caus
lysosom acid lipas defici lal-d
genet disord character
loss lysosom acid lipidas
need break lipid
result accumul fat organ
lead liver diseas cardiovascular
without treatment median age death
month infant lal-d
therapi statin stem cell transplant
estim preval per
acquir acquisit synagevain
approv decemb
recombin form lysosom acid lipas
demonstr surviv rate infant
lal-d one year compar
competit product develop
cholesterol
lipid
cleav free
defici lal
free cholesterol
product develop
amyloid light-chain al amyloidosi caus misfold
progress diseas caus deposit
amyloid result sever organ damag
patient die within one year
affect patient eu
new case year
current treatment includ chemotherapi
stop growth abnorm amyloid-
transplant asct support care
chemotherapi remov previous
deposit amyloid patient
elig asct
organ affect al amyloidosi
short breath
lead congest heart failur
larg amount protein urin
swell feet/leg
transplant requir
sensat hands/feet
produc plasma
cell bone marrow
organ
chimer mab specif kappa lambda
light chain remov amyloid deposit organ
treatment al amyloidosi
vivo imag patient show
bind deposit heart liver kidney
phase trial show median time
ntprobnpin treat patient
three week compar month
standard care treat patient
overal surviv month
expect initi phase ii/iii trial earli
overal organ respons rate phase ia/ib al amyloid
overal organ respons rate phase ia/ib al amyloid
mean improv mean gl score
phase patient week
cardiac patient improv
statist signific improv seen
genet disord caus mutat
gene result
character toxic accumul
copper liver brain organ
diseas present birth symptom
emerg copper build
preval
estim case
case
standard care use chelat agent
make metal ion form stabl water
tissu
improv disabl ncccorr level neurolog
state regardless cirrhosi
novel oral copper-protein bind agent promot copper remov liver
reduc ncccorrlevel similar extent patient without cirrhosi baselin week
stabil reduc disabl improv neurolog statu
improv maintain week
on-going phase trial expect complet data expect
potenti first-lin treatment standard care
conduct liver biopsi studi supplement find
cirrhosi bl
cirrhosi bl
cirrhosi bl
cirrhosi bl
cirrhosi bl
cirrhosi bl
fcrnmediat bidirect transport
recycl igg epitheli cell bind
igg acid endosom releas
circul cell surfac
condit neutral
fcrnactiv prevent igg undergo
lysosom degrad contribut
sever autoimmun disord caus
reaction self antigen igg
disrupt fcrn-igg interact increas
clearanc igg believ reduc
level pathogen autoantibodi
degrad lysosom
expand alexion presenc fcrn space
on-going phase sad/mad clinic trial
compani assess potenti indic
futur develop
develop collabor affibodi
optim home use
higher dose per
mab
protein high bind
long durat action
half-lif
significantli longer
due albumod
technolog albumin
potenti longer-act
could first approv therapi waiha
acquir syntimmuneacquisit
proof concept establish phase ib/iia
studi rapid onset action
high igg specif reduct
data phase i/ii studi gmgand
waiha expect
potenti first-to-market fcrnand first-
line treatment waiha
anticip iv dose phase studi
expect late
plan pursu subqformul initi
trial end
induc rapid clearanc monomer multimer igg
tiggperc baselin
cicperc baselin
could expand gmg franchis hematolog
total gmg popul patient
refractori gmg
patient
patient
continu activ diseas despit treatment
first anti-fcrnin develop waiha
mode administr
mechan action
stage clinic development/
novel anti-albumin bispecif
prevent activ human
kdasiz specif potenti
auto-injector pre-fil syring subq
dose long half-lif
first-in-human studi anticip
develop multipl indic
busi develop collabor
acquisit synageva view one
worst deal histori
deal predict accret gaap
earn per share
discontinu result
slow kanumagrowth discontinu
viabl clinic asset caus
investor scrutini lack roi
deal valu billion
hypothesi kanumawould billion-
kanumagener revenu
million last year
acquisit project lead four
candid enter clinic
includ drug candid
treatment mp iiib
alexion discontinu develop
fourth quarter due
priorit clinic develop
sinc alexion spent billion collabor
partnership acquisit
million
acquisit wilson therapeut view
gener posit street
wilson sweden-bas
biopharma compani special
develop therapi rare copper-
acquir wilson therapeut ab april
million
done attempt augment pipelin
strong fit given alexion focu
metabol neurolog disord
drug phase develop
 orphan drug design fast track
line ceo commit revamp
pipelin futur growth
acquisit syntimmun secur anti-
fcrn asset clinic develop waiha
transact valu billion
payment million
potenti addit mileston
payment million
syntimmunehad develop
human monoclon
antibodi inhibit fcrn-igg complex
studi phase ib/iiastudi
patient waiha pemphigu vulgari
pv pemphigu foliaceu pf
demonstr proof mechan
collabor caelum bioscienc develop
therapi al amyloidosi
caelum clinical-stag biotech compani
develop treatment rare diseas
compani collabor design
develop al amyloidosi
signific improv global
longitudin strain correl
patient surviv
caelum respons develop
phase ii manufactur cael-
alexion acquir minor equiti interest
caelum retain option acquir
remain equiti caelum base phase ii
caelum receiv million equiti
invest milestone-depend
potenti addit million
regulatori commerci mileston
payment event alexion
partnership affibodi co-develop
igg mediat autoimmun diseas
partnership announc march
alexion provid affibodywith up-front
payment million
potenti addit develop
sales-bas mileston million
low-double-digit royalti payment
alexion lead joint clinic develop
commerci activ
affibodyha option co-promot
 lead clinic develop
undisclos indic
compani base sweden proprietari
affibodymolecul albumondtechnolog
psoriasi igg-medi autoimmun
collabor zealand pharma aim expand
announc march
discov develop novel subcutan
deliv peptid therapi complement-
peptid highli select potent
allow potenti treatment wide
rang complement-medi diseas
zealand lead discoveri research
effort preclin stage
alexion lead develop begin
ind file phase studi
zealand receiv up-front payment
million equiti invest million
potenti addit develop
mileston million sale
mileston million lead target
potenti high-single-digit low-double-
digit royalti payment lead target
alexion exclus world-wide licens
commerci right one preclin target
option three addit target
select option fee million
potenti addit mileston
royalti payment lower price
edio bridgebiosubsidiari receiv up-
front payment million equiti
invest million
potenti addit japanese-bas
mileston royalty-depend
announc septemb
alexion given exclus licens develop
commerci japan
small molecul bind
stabil ttr blood underli
caus transthyretin amyloidosi attr
evalu phase studi
 europ attr
phase studi treatment
attr polyneuropathi attr-pn
partnership co-develop complement
inhibitor address
complement pharma receiv
million mileston payment phase
alexion option acquir complement
blood brain barrier
enter
circul
lead
format
caus
bind
peripher reduc
level
decreas
partnership allow alexion use halozym
enhanz drug deliveri technolog
develop subcutan formul four
halozymereceiv million up-front
potenti earn million
target develop midsingle-digit
halozymealso agreement roch
baxalta janssen bm
partnership develop rnai therapeut
alexion exclus world-wide licens
commerci right two dicerna
preclin galxcrnai molecul
exclus option two addit galxc
dicernareceiv up-front payment
million alexion made addit
potenti mileston million per
possibl busi develop deal could
